These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review. Wang W; Cheng J; Mallon C; Al-Marrawi MY; Holder S; Joshi M; Kaag M; Talamo G; Drabick JJ Clin Genitourin Cancer; 2015 Dec; 13(6):e391-5. PubMed ID: 26303589 [No Abstract] [Full Text] [Related]
47. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. Park CY Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356 [TBL] [Abstract][Full Text] [Related]
48. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Nicholaou T; Wong R; Davis ID Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435 [No Abstract] [Full Text] [Related]
49. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer. Berchem G; Dewilde S; Mahassen P Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172 [TBL] [Abstract][Full Text] [Related]
51. The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López. Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb S; Shamash J; Stockdale A; Lim L; Nathan P; Chowdury S Eur J Cancer; 2013 Mar; 49(4):986-7. PubMed ID: 23138000 [No Abstract] [Full Text] [Related]
52. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Motzer RJ; Michaelson MD; Redman BG; Hudes GR; Wilding G; Figlin RA; Ginsberg MS; Kim ST; Baum CM; DePrimo SE; Li JZ; Bello CL; Theuer CP; George DJ; Rini BI J Clin Oncol; 2006 Jan; 24(1):16-24. PubMed ID: 16330672 [TBL] [Abstract][Full Text] [Related]
53. Home blood-pressure monitoring in patients receiving sunitinib. Azizi M; Chedid A; Oudard S N Engl J Med; 2008 Jan; 358(1):95-7. PubMed ID: 18172185 [No Abstract] [Full Text] [Related]
54. Two new drugs for renal cell carcinoma. Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624 [No Abstract] [Full Text] [Related]
55. PISCES trial: the end does not always justify the means. Barni S; Petrelli F J Clin Oncol; 2014 Nov; 32(33):3782-3. PubMed ID: 25267749 [No Abstract] [Full Text] [Related]
56. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. Karashima T; Inoue K; Fukata S; Iiyama T; Kurabayashi A; Kawada C; Shuin T Int J Oncol; 2007 Apr; 30(4):937-45. PubMed ID: 17332933 [TBL] [Abstract][Full Text] [Related]
57. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Narayanan S; Callis-Duffin K; Batten J; Agarwal N Am J Med Sci; 2010 Jun; 339(6):580-1. PubMed ID: 20421784 [TBL] [Abstract][Full Text] [Related]
58. Reply to S. Barni et Al and M. Sun et Al. Garnick MB J Clin Oncol; 2014 Nov; 32(33):3785. PubMed ID: 25267752 [No Abstract] [Full Text] [Related]
59. Reply to S. Barni et Al and M. Sun et Al. Escudier B; Porta C; Powles T; Eisen T; Sternberg CN; Mehmud F; Cella D J Clin Oncol; 2014 Nov; 32(33):3783-4. PubMed ID: 25267750 [No Abstract] [Full Text] [Related]
60. How to interpret patient preferences in selecting the best drug: are the current measurements up to the job? Garnick MB J Clin Oncol; 2014 May; 32(14):1392-3. PubMed ID: 24687838 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]